ArticleFrontiers in oncology2019
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis.International journal of molecular sciences · 2026Review
- Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer.Pharmaceutics · 2026Article
- In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Mitochondrial-mediated apoptosis as a therapeutic target for FNC (2'-deoxy-2'-b-fluoro-4'-azidocytidine)-induced inhibition of Dalton's lymphoma growth and proliferation.Discover oncology · 2024Article
- Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer.Frontiers in oncology · 2023Review
- Sustained delivery of PARP inhibitor Talazoparib for the treatment ofFrontiers in oncology · 2023Article
- Intraperitoneal administration of thermosensitive hydrogel Co-loaded with norcantharidin nanoparticles and oxaliplatin inhibits malignant ascites of hepatocellular carcinoma.Drug delivery · 2022Article
- Development of the PARP inhibitor talazoparib for the treatment of advancedExpert opinion on pharmacotherapy · 2021Review
- Recent Developments in Nanomedicine for Pediatric Cancer.Journal of clinical medicine · 2021Review
- Quantification of Cellular Drug Biodistribution Addresses Challenges in EvaluatingAdvanced therapeutics · 2021Article
- The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression.Cell proliferation · 2020Review
- Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.Frontiers in chemistry · 2020Review
- A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.Theranostics · 2019Article
- Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Talazoparib, a potent PARP inhibitor, induces synthetic lethality in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.